VARIX
MCID: VRC005
MIFTS: 60

Varicose Veins (VARIX)

Categories: Blood diseases, Cardiovascular diseases, Skin diseases

Aliases & Classifications for Varicose Veins

MalaCards integrated aliases for Varicose Veins:

Name: Varicose Veins 56 12 6 42 43 15 62 62
Varices 12 15
Venous Ectasia 12
Venous Varices 12
Varicosity 71
Varix 12

Characteristics:

OMIM:

56
Inheritance:
multifactorial vs. autosomal or x-linked dominant


HPO:

31

Classifications:



External Ids:

Disease Ontology 12 DOID:799
OMIM 56 192200
MeSH 43 D014648
NCIt 49 C35114
SNOMED-CT 67 128060009
ICD10 32 I83.90
MedGen 41 C0042345
SNOMED-CT via HPO 68 12856003 399989005
UMLS 71 C0042345

Summaries for Varicose Veins

MedlinePlus : 42 Varicose veins are swollen, twisted veins that you can see just under the skin. They usually occur in the legs, but also can form in other parts of the body. Hemorrhoids are a type of varicose vein. Your veins have one-way valves that help keep blood flowing toward your heart. If the valves are weak or damaged, blood can back up and pool in your veins. This causes the veins to swell, which can lead to varicose veins. Varicose veins are very common. You are more at risk if you are older, are female, have obesity, don't exercise, or have a family history of varicose veins. They can also be more common in pregnancy. Doctors often diagnose varicose veins from a physical exam. Sometimes you may need additional tests. Exercising, losing weight, elevating your legs when resting, and not crossing them when sitting can help keep varicose veins from getting worse. Wearing loose clothing and avoiding long periods of standing can also help. If varicose veins are painful or you don't like the way they look, your doctor may recommend procedures to remove them. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Varicose Veins, also known as varices, is related to klippel-trenaunay-weber syndrome and varicocele, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Varicose Veins is ELN (Elastin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Carvedilol and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and colon, and related phenotypes are varicose veins and homeostasis/metabolism

Disease Ontology : 12 A vein disease that is characterized by swollen, twisted veins visible just under the surface of the skin.

PubMed Health : 62 About varicose veins: Varicose (VAR-i-kos) veins are swollen, twisted veins that you can see just under the surface of the skin. These veins usually occur in the legs, but they also can form in other parts of the body. Varicose veins are a common condition. They usually cause few signs and symptoms. Sometimes varicose veins cause mild to moderate pain, blood clots, skin ulcers (sores), or other problems.

Wikipedia : 74 Varicose veins are superficial veins that have become enlarged and twisted. Typically they occur just... more...

More information from OMIM: 192200

Related Diseases for Varicose Veins

Diseases related to Varicose Veins via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 941)
# Related Disease Score Top Affiliating Genes
1 klippel-trenaunay-weber syndrome 33.7 FOXC2 F2 AGGF1
2 varicocele 33.3 TNF SHBG MTHFR IL6 HIF1A
3 budd-chiari syndrome 32.7 SERPINC1 MTHFR F2
4 chronic venous insufficiency 32.1 VEGFA TIMP2 TIMP1 MMP9 MMP1 F2
5 thrombophilia due to thrombin defect 31.9 SERPINC1 MTHFR F2
6 vascular disease 31.9 VWF VEGFA TNF TIMP1 SERPINC1 MTHFR
7 venous insufficiency 31.8 VWF VEGFA TIMP2 TIMP1 MTHFR MMP9
8 thrombosis 31.7 VWF SERPINC1 MTHFR F2
9 lipodermatosclerosis 31.7 VEGFA TIMP2 MMP1
10 thrombophlebitis 31.7 VWF TNF SERPINC1 MTHFR F2
11 pulmonary embolism 31.7 VWF SERPINC1 MTHFR F2
12 portal hypertension 31.5 VWF VEGFA TNF F2 ELN
13 post-thrombotic syndrome 31.5 SERPINC1 IL6 F2
14 biliary atresia 31.4 TNF TIMP1 F2
15 hemorrhoid 31.4 TNF MMP9 F2
16 gastric ulcer 31.3 VEGFA TNF IL6
17 thrombophilia 31.2 VWF SERPINC1 MTHFR F2
18 vein disease 31.1 VWF VEGFA TNF SERPINC1 MTHFR IL6
19 portal vein thrombosis 30.9 SERPINC1 MTHFR F2
20 patent foramen ovale 30.9 VWF SERPINC1 MTHFR F2 ELN
21 hepatoportal sclerosis 30.9 F2 ELN
22 inguinal hernia 30.9 TIMP2 TIMP1 MMP9 MMP2 MMP1 IL6
23 hemangioma 30.9 VWF VEGFA MMP9 HIF1A F2
24 pyoderma 30.9 TNF MMP9 MMP1
25 pyoderma gangrenosum 30.9 TNF MMP9 MMP1
26 mitral valve disease 30.8 MMP1 F2 ELN
27 fasciitis 30.8 TNF MMP1 IL6
28 adenocarcinoma 30.8 VEGFA TIMP2 TIMP1 MMP9 MMP2
29 thrombotic microangiopathy 30.8 VWF VEGFA
30 neuritis 30.8 TNF MMP9 IL6
31 compartment syndrome 30.7 TNF SERPINC1 IL6 F2
32 sclerosing cholangitis 30.7 TNF IL6 F2
33 obstructive jaundice 30.6 TNF IL6 F2
34 meningitis 30.6 VEGFA TNF MMP9 IL6
35 protein s deficiency 30.6 SHBG SERPINC1 MTHFR F2
36 alcoholic liver cirrhosis 30.6 TNF IL6 F2
37 cutis laxa 30.6 MMP9 MMP3 MMP2 MMP1 ELN
38 mitral valve stenosis 30.6 VWF SERPINC1 F2
39 protein c deficiency 30.6 SERPINC1 MTHFR F2
40 placental abruption 30.6 SERPINC1 MTHFR F2
41 cavernous hemangioma 30.6 VEGFA SERPINC1 F2
42 capillary hemangioma 30.6 VWF VEGFA HIF1A
43 migraine with or without aura 1 30.5 TNF MTHFR MMP9 IL6 F2
44 intraocular pressure quantitative trait locus 30.5 VEGFA TIMP2 MMP1 FOXC2 ELN
45 erysipelas 30.5 TNF IL6 ELN
46 iron deficiency anemia 30.5 TNF IL6 HIF1A
47 atrial heart septal defect 30.5 SERPINC1 MTHFR F2 ELN
48 intravascular papillary endothelial hyperplasia 30.5 VEGFA HIF1A
49 deficiency anemia 30.5 TNF SERPINC1 IL6 HIF1A
50 alcoholic hepatitis 30.5 TNF IL6 F2

Graphical network of the top 20 diseases related to Varicose Veins:



Diseases related to Varicose Veins

Symptoms & Phenotypes for Varicose Veins

Human phenotypes related to Varicose Veins:

31
# Description HPO Frequency HPO Source Accession
1 varicose veins 31 HP:0002619

Symptoms via clinical synopsis from OMIM:

56
Vascular:
varicose veins

Misc:
twice as frequent in females as in males

Clinical features from OMIM:

192200

UMLS symptoms related to Varicose Veins:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Varicose Veins:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 F2 FOXC2 HIF1A IL6 LGALS3BP MMP1
2 cardiovascular system MP:0005385 10.29 AGGF1 F2 FOXC2 HIF1A IL6 MMP2
3 immune system MP:0005387 10.24 F2 FOXC2 HIF1A IL6 LGALS3BP MMP1
4 hematopoietic system MP:0005397 10.21 F2 HIF1A IL6 MMP2 MMP3 MMP9
5 nervous system MP:0003631 10.1 AGGF1 F2 FOXC2 HIF1A IL6 MMP2
6 digestive/alimentary MP:0005381 10.06 F2 FOXC2 HIF1A IL6 MMP9 TNF
7 neoplasm MP:0002006 9.97 AGGF1 HIF1A IL6 MMP1 MMP2 MMP9
8 respiratory system MP:0005388 9.85 AGGF1 F2 FOXC2 HIF1A IL6 MMP2
9 skeleton MP:0005390 9.7 F2 FOXC2 HIF1A IL6 MMP2 MMP3
10 vision/eye MP:0005391 9.28 FOXC2 HIF1A IL6 MMP2 MMP9 MTHFR

Drugs & Therapeutics for Varicose Veins

PubMed Health treatment related to Varicose Veins: 62

Varicose veins are treated with lifestyle changes and medical procedures. The goals of treatment are to relieve symptoms, prevent complications, and improve appearance. If varicose veins cause few symptoms, your doctor may simply suggest making lifestyle changes. If your symptoms are more severe, your doctor may recommend one or more medical procedures. For example, you may need a medical procedure if you have a lot of pain, blood clots, or skin disorders caused by your varicose veins. Some people who have varicose veins choose to have procedures to improve how their veins look. Although treatment can help existing varicose veins , it can't keep new varicose veins from forming.

Drugs for Varicose Veins (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
4
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
5
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
6
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
7
Vancomycin Approved Phase 4 1404-90-6 14969 441141
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
10
Azithromycin Approved Phase 4 83905-01-5 447043 55185
11 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
12
Ethanolamine oleate Approved Phase 4 2272-11-9
13
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
14
Thrombin Approved, Investigational Phase 4
15
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
16
Dalteparin Approved Phase 4 9005-49-6
17
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
18
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
19
Pantoprazole Approved Phase 4 102625-70-7 4679
20
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
21
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
22
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
23
Nitric Oxide Approved Phase 4 10102-43-9 145068
24
Warfarin Approved Phase 4 81-81-2 6691 54678486
25
Prazosin Approved Phase 4 19216-56-9 4893
26
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
27
Phylloquinone Approved, Investigational Phase 4 84-80-0
28
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
29 Bemiparin Approved, Investigational Phase 4 91449-79-5
30
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
31
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
32
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
33
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
34
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
35
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
36
Racepinephrine Approved Phase 4 329-65-7 838
37
Hesperidin Approved, Investigational Phase 4 520-26-3 53477767
38
Ibuprofen Approved Phase 4 15687-27-1 3672
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
40
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
41 Menaquinone Investigational Phase 4 1182-68-9
42 Adrenergic alpha-Antagonists Phase 4
43 Hormones Phase 4
44 Antioxidants Phase 4
45 Adrenergic alpha-1 Receptor Antagonists Phase 4
46 Protective Agents Phase 4
47 Calcium, Dietary Phase 4
48 calcium channel blockers Phase 4
49 Anti-Bacterial Agents Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 481)
# Name Status NCT ID Phase Drugs
1 The Impact of Early Feeding Following Ligation of the Acute Bleeding Varices Unknown status NCT01287702 Phase 4
2 Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
3 Compression Versus Anti-Embolism Stockings in Patients With Leg Edema: Objective Investigation of Interface Compression and Edema Measurements, Clinical Outcomes, and Quality of Life. Unknown status NCT00766974 Phase 4
4 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
5 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
6 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
7 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
8 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
9 Banding Ligation With Carvedilol vs. Carvedilol for the Prevention of First Bleeding in Cirrhotics With Moderate Varices Unknown status NCT01383044 Phase 4 carvedilol
10 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
11 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
12 Prevention of Esophageal Variceal Rebleeding Unknown status NCT00863837 Phase 4 terlipressin (vasoconstrictor);pantoloc (proton pump inhibitor)
13 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
14 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
15 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
16 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
17 PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL Completed NCT01893541 Phase 4 PROPRANOLOL
18 Multicenter Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena® Compared to Radiofrequency Ablation Completed NCT02462720 Phase 4 Varithena®
19 Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient Completed NCT02346058 Phase 4 Esarin Gel
20 Comparison of Endoscopic Injection of Conventional and Double Doses Cyanoacrylate for Gastric Variceal Hemorrhage Completed NCT00735358 Phase 4
21 Comparison of Surgery Versus Foam Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis Completed NCT02010723 Phase 4 sclerotherapy with aethoxysclerol foam
22 Efficacy of Alkalinised 2% Mepivacaine for Local Infiltration Anesthesia, in Ambulatory Phlebectomy Completed NCT01611324 Phase 4 Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%;Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%
23 Radiofrequency Endovenous ClosureFAST vs. Laser Ablation for the Treatment of Great Saphenous Reflux: A Multicenter, Single-Blinded, Randomized Study (RECOVERY) Completed NCT00509392 Phase 4
24 Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial Completed NCT02657252 Phase 4 Glucose;Polidocanol with Glucose
25 A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs. Completed NCT02054325 Phase 4 Polidocanol with Glucose;Glucose
26 Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease Completed NCT01654016 Phase 4 Detralex
27 Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
28 RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide Completed NCT00966355 Phase 4 Terlipressin;Somatostatin;Octreotide
29 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
30 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
31 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein: A Prospective Randomized Trial Completed NCT02236338 Phase 4
32 Management of Superficial Thrombophlebitis Completed NCT00264381 Phase 4 Dalteparin sodium injection
33 Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial Completed NCT02119884 Phase 4 Terlipressin;Octreotide
34 A Controlled Trial of Nadolol Plus Isosorbide Mononitrate vs. Carvedilol for the Prevention of Variceal Rebleeding Completed NCT01103154 Phase 4 carvedilol;nadolol + ISMN
35 A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed NCT03175731 Phase 4 Proton Pump Inhibitors;Placebo
36 A Randomized, Controlled Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis Completed NCT00921349 Phase 4 Nadolol
37 Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding Completed NCT02504723 Phase 4 carvedilol;cyanoacrylate
38 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
39 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
40 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
41 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
42 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
43 Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
44 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone;ceftrioxone
45 A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding Completed NCT01112852 Phase 4 pantoloc 40 mg;somatostatin or terlipressin
46 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
47 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
48 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
49 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
50 RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment Recruiting NCT00966082 Phase 4

Search NIH Clinical Center for Varicose Veins

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Sodium Morrhuate
Sodium Tetradecyl Sulfate

Cochrane evidence based reviews: varicose veins

Genetic Tests for Varicose Veins

Anatomical Context for Varicose Veins

MalaCards organs/tissues related to Varicose Veins:

40
Liver, Spleen, Colon, Skin, Testes, Heart, Kidney

Publications for Varicose Veins

Articles related to Varicose Veins:

(show top 50) (show all 19707)
# Title Authors PMID Year
1
Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. 56 61
15744037 2005
2
A contribution to the problem of the inheritance of primary varicose veins. 61 56
4435791 1974
3
Genetics of varicose veins of the lower extremities. 61 56
5365895 1969
4
Effectiveness of tumescent solution combined with negative pressure wound therapy in traditional high ligation and stripping of the great saphenous vein. 61 42
32176031 2020
5
A retrospective cohort study comparing two treatments for active venous leg ulcers. 61 42
32080149 2020
6
Familiar congenital absence of valves in the deep leg veins. 56
4426629 1974
7
The heredity of venous insufficiency. 56
13561707 1958
8
Validation of predictive factors for infection in adults with chronic leg ulcers: A prospective longitudinal study. 42
31891202 2020
9
Expression of vascular endothelial growth factor and its receptors in infertile men with varicocele. 61
32361601 2020
10
Endovenous Laser Ablation with and Without Concomitant Phlebectomy for the Treatment of Varicose Veins: A Retrospective Analysis of 954 Limbs. 61
31917221 2020
11
Surgical management of a large postoperative vulvar haematoma following vulvar phlebectomy and ovarian vein embolization for vulvar varicose veins: A case report. 61
32489909 2020
12
A Rare Presentation of Colonic Hemangiomas and Varices. 61
30981001 2020
13
Modified Coil-Assisted Retrograde Transvenous Obliteration (m-CARTO) for Gastric Varices. 61
32382860 2020
14
Catheter-directed foam sclerotherapy, an alternative to ultrasound-guided foam sclerotherapy for varicose vein treatment: A systematic review and meta-analysis. 61
31918640 2020
15
The frequency and clinical significance of nontarget superficial and deep vein occlusion after physician compounded foam sclerotherapy of varicose tributaries. 61
31924136 2020
16
Iliac Vein Stenting for Chronic Proximal Venous Outflow Obstruction in a Predominantly Asian-American Cohort. 61
31931130 2020
17
Is coffee ground vomiting important? Findings from a large bleeding unit database and outcomes at 30 days. 61
32175981 2020
18
Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery. 61
32124212 2020
19
IGFBP6 regulates vascular smooth muscle cell proliferation and morphology via cyclin E-CDK2. 61
32529639 2020
20
Impurity identification and quantification for arginine vasopressin by liquid chromatography/high-resolution mass spectrometry. 61
32247289 2020
21
Severe varicose veins and the risk of mortality: a nationwide population-based cohort study. 61
32565451 2020
22
Study of association of varicose veins and inflammation by inflammatory markers. 61
32529904 2020
23
Outcomes Following Truncal Ablation With or Without Concomitant Phlebectomy for Isolated Symptomatic Varicose Veins (C2 disease). 61
32502731 2020
24
Contact allergy due to platinum siloxane complex in elastic compression stockings for varicose veins. 61
32511772 2020
25
Randomised controlled study to compare radiofrequency ablation with minimally invasive ultrasound-guided non-flush ligation and stripping of great saphenous vein in the treatment of varicose veins. 61
32538106 2020
26
Non-invasive prediction model for high-risk esophageal varices in the Chinese population. 61
32550759 2020
27
Transparent cap-assisted endoscopic injection sclerotherapy for the treatment of patients with esophageal varices. 61
32541523 2020
28
Colonic varices treated with embolization after pancreatoduodenectomy with portal vein resection: a case report. 61
32494925 2020
29
Timeline of Postoperative Changes After KTP Vaporization of True Vocal Fold Varices. 61
30961384 2020
30
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. 61
32557193 2020
31
Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. 61
32562889 2020
32
Utility of Transabdominal Ultrasonography Enhanced by Oral Cellulose-Based Contrast Agent in Depicting Varices at Cardia and Fundus. 61
32217027 2020
33
Noninvasive evaluation of esophageal varices in cirrhotic patients based on spleen hemodynamics: a dual-energy CT study. 61
32072256 2020
34
Risk of rebleeding from gastroesophageal varices after initial treatment with cyanoacrylate; a systematic review and pooled analysis. 61
32517718 2020
35
Deciding Among Noninvasive Tools for Predicting Varices Needing Treatment in Chronic Liver Disease: An Analysis of Asian Cohort. 61
32516202 2020
36
Clinical significance of isolated gastric varices in liver cirrhotic patients: A single-referral-centre retrospective cohort study. 61
32514463 2020
37
CASS (CyanoAcrylate closure versus Surgical Stripping for incompetent saphenous veins) study: a randomized controlled trial comparing clinical outcomes after cyanoacrylate closure and surgical stripping for the treatment of incompetent saphenous veins. 61
32493398 2020
38
Diagnosis and Treatment of Postthrombotic Syndrome. 61
32455461 2020
39
Assessing Baveno VI criteria with liver stiffness measured using a new point-shear wave elastography technique (BAVElastPQ study). 61
32510772 2020
40
Long-term results of variceal bleeding management in 302 patients with chronic extrahepatic portal vein obstruction. 61
31677186 2020
41
2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. 61
32180327 2020
42
The left splenorenal venous shunt decreases clinical signs of sinistral portal hypertension associated with splenic vein ligation during pancreaticoduodenectomy with venous resection. 61
32536489 2020
43
Deep vein sclerosis following sclerotherapy: Ultrasonic and d-dimer criteria. 61
31510866 2020
44
The intravascular ultrasound morphometry of iliac veins in subjects without severe chronic venous insufficiency and its implications for treatment indications and stent size selection. 61
31645193 2020
45
Gastric Varices. 61
32511955 2020
46
Cirrhosis and Bleeding Esophageal Varices: Historic Perspectives. 61
32500417 2020
47
Choledochal varices: An uncommon cholangioscopic finding. 61
32081376 2020
48
Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. 61
32515534 2020
49
Sudden death due to ruptured oesophageal varices - autopsy-based case report. 61
32502364 2020
50
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity. 61
32487541 2020

Variations for Varicose Veins

ClinVar genetic disease variations for Varicose Veins:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ELN NM_000501.4(ELN):c.898A>T (p.Thr300Ser)SNV Uncertain significance 523433 rs766735416 7:73466262-73466262 7:74051932-74051932

Expression for Varicose Veins

Search GEO for disease gene expression data for Varicose Veins.

Pathways for Varicose Veins

Pathways related to Varicose Veins according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 VWF VEGFA TNF TIMP2 TIMP1 MMP9
2
Show member pathways
13.32 VWF VEGFA TNF TIMP1 MMP9 MMP3
3
Show member pathways
13.29 VWF VEGFA TIMP1 SERPINC1 MMP1 LGALS3BP
4 12.84 VEGFA MMP9 MMP2 MMP1 IL6 HIF1A
5
Show member pathways
12.73 TIMP2 TIMP1 MMP9 MMP3 MMP2 MMP1
6
Show member pathways
12.58 TNF TIMP1 MMP2 IL6 F2
7
Show member pathways
12.34 TNF MMP9 MMP3 MMP1 IL6
8
Show member pathways
12.31 TNF MTHFR IL6 F2
9 12.3 VEGFA TNF MMP9 MMP2 HIF1A
10
Show member pathways
12.29 VEGFA TIMP1 MMP3 MMP1 HIF1A
11 12.17 VEGFA TNF IL6 HIF1A
12 12.13 VEGFA TNF MMP9 MMP2 MMP1 IL6
13 12.09 VEGFA TNF MMP9 MMP2
14 12.06 TNF IL6 HIF1A FOXC2
15 11.98 TNF MMP9 MMP3 IL6
16 11.96 VEGFA TIMP1 IL6 HIF1A
17 11.92 VEGFA TNF MMP2 IL6
18 11.86 VEGFA TNF MMP3 MMP1 IL6
19
Show member pathways
11.8 TNF TIMP2 TIMP1 MMP9 MMP3 MMP2
20 11.75 VEGFA MMP9 MMP2 MMP1
21 11.66 MMP9 MMP2 HIF1A
22 11.65 MMP9 MMP2 IL6
23 11.65 VWF TIMP2 TIMP1 MMP9 MMP3 MMP2
24 11.64 TNF TIMP1 MMP9 MMP2 IL6 ELN
25 11.58 TIMP2 TIMP1 MMP9 MMP3 MMP2 MMP1
26 11.57 VEGFA MMP1 IL6 HIF1A
27 11.55 TNF MMP2 IL6
28 11.53 TNF MMP9 MMP2 IL6
29 11.52 TNF TIMP1 IL6
30 11.39 TIMP2 MMP9 MMP3 MMP1 ELN
31 11.36 MMP9 MMP2 MMP1 IL6
32 11.33 VEGFA TNF TIMP1 MMP9 MMP3 MMP2
33 11.31 TNF MTHFR IL6
34
Show member pathways
11.3 VEGFA TNF MMP9 MMP3 MMP2 MMP1
35
Show member pathways
11.29 VEGFA TIMP1 HIF1A
36 11.18 TIMP2 TIMP1 MMP9 F2
37 11.14 VEGFA TIMP2 MMP9 HIF1A
38 11.11 MMP2 MMP1 F2
39 11.05 VEGFA TIMP1 MMP1
40 10.63 VEGFA HIF1A

GO Terms for Varicose Veins

Cellular components related to Varicose Veins according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10 VEGFA TNF TIMP2 TIMP1 SERPINC1 MMP9
2 collagen-containing extracellular matrix GO:0062023 9.76 VWF TIMP2 SERPINC1 MMP9 MMP2 LGALS3BP
3 extracellular matrix GO:0031012 9.56 VEGFA TIMP2 TIMP1 MMP9 MMP3 MMP2
4 extracellular region GO:0005576 9.53 VWF VEGFA TNF TIMP2 TIMP1 SHBG
5 platelet alpha granule lumen GO:0031093 9.5 VWF VEGFA TIMP1

Biological processes related to Varicose Veins according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.88 VEGFA TNF MMP9 F2
2 response to hypoxia GO:0001666 9.85 VEGFA MTHFR MMP2 HIF1A
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA TNF IL6
4 platelet degranulation GO:0002576 9.8 VWF VEGFA TIMP1 LGALS3BP
5 positive regulation of endothelial cell proliferation GO:0001938 9.79 VEGFA HIF1A AGGF1
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF MMP2 IL6
7 response to hormone GO:0009725 9.77 TIMP2 TIMP1 FOXC2
8 hemostasis GO:0007599 9.75 VWF SERPINC1 F2
9 outflow tract morphogenesis GO:0003151 9.74 VEGFA HIF1A ELN
10 cellular protein metabolic process GO:0044267 9.73 TIMP1 SERPINC1 MMP2 MMP1 IL6 F2
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 TNF MMP9 MMP2
12 positive regulation of protein complex assembly GO:0031334 9.71 VEGFA TNF MMP3 MMP1
13 extracellular matrix organization GO:0030198 9.7 VWF TNF MMP9 MMP3 MMP2 MMP1
14 lactation GO:0007595 9.69 VEGFA SERPINC1 HIF1A
15 positive regulation of JAK-STAT cascade GO:0046427 9.65 TNF IL6 F2
16 negative regulation of lipid storage GO:0010888 9.63 TNF IL6
17 positive regulation of chemokine production GO:0032722 9.63 TNF IL6 HIF1A
18 collagen catabolic process GO:0030574 9.62 MMP9 MMP3 MMP2 MMP1
19 negative regulation of metallopeptidase activity GO:1905049 9.61 TIMP2 TIMP1
20 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.61 TIMP2 TIMP1
21 response to amyloid-beta GO:1904645 9.61 MMP9 MMP3 MMP2
22 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.56 VEGFA HIF1A
23 regulation of neuroinflammatory response GO:0150077 9.54 MMP9 MMP3 IL6
24 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.52 TIMP1 HIF1A
25 extracellular matrix disassembly GO:0022617 9.43 TIMP2 TIMP1 MMP9 MMP3 MMP2 MMP1
26 cytokine-mediated signaling pathway GO:0019221 9.28 VEGFA TNF TIMP1 MMP9 MMP3 MMP2

Molecular functions related to Varicose Veins according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.91 TIMP2 TIMP1 MMP9 MMP3 MMP2 MMP1
2 cytokine activity GO:0005125 9.71 VEGFA TNF TIMP1 IL6
3 metallopeptidase activity GO:0008237 9.67 MMP9 MMP3 MMP2 MMP1
4 growth factor activity GO:0008083 9.62 VEGFA TIMP1 IL6 F2
5 metalloendopeptidase activity GO:0004222 9.56 MMP9 MMP3 MMP2 MMP1
6 endopeptidase activity GO:0004175 9.46 MMP9 MMP3 MMP2 MMP1
7 serine-type endopeptidase activity GO:0004252 9.35 MMP9 MMP3 MMP2 MMP1 F2
8 protease binding GO:0002020 9.02 VWF TNF TIMP2 TIMP1 SERPINC1

Sources for Varicose Veins

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....